William N Washburn1. 1. Senior Research Fellow, Metabolic Diseases Chemistry, Research and Development, Bristol-Myers Squibb Co., PO Box 5400, Princeton, NJ 08543, USA. william.washburn@bms.com
Abstract
BACKGROUND: A critical factor for maintenance of glucose balance is the renal recovery of glucose from the glomerular filtrate mediated primarily by sodium glucose co-transporter 2 (SGLT2). This capacity can be modulated by SGLT2 inhibitors thereby providing a unique insulin independent method of treatment of diabetes. OBJECTIVE/ METHOD: A discussion of the evolution of SGLT inhibitors as inferred from patents published from 2005 to 2009 is prefaced by a brief review of the role of SGLT in glucose transport and the clinical findings illustrating the therapeutic potential of SGLT inhibitors as anti-diabetic agents. These compounds comprise O, C and N-glycosides generated by attachment of an appropriate lipophilic aglycone component to a suitable glucose analogue. CONCLUSION: The realization that the in vivo potency of O-glucosides was markedly less than that of C-glucosides necessitated a shift in medicinal chemistry focus of the pharmaceutical companies pursuing SGLT2 inhibitors. Particular emphasis is placed on the strategy that each used to circumvent the constraints imposed by prior art while utilizing a common pharmacophore. The role of SGLT2 inhibitors for treatment of diabetes will be established by the outcome of the five compounds in advanced clinical trials.
BACKGROUND: A critical factor for maintenance of glucose balance is the renal recovery of glucose from the glomerular filtrate mediated primarily by sodium glucose co-transporter 2 (SGLT2). This capacity can be modulated by SGLT2 inhibitors thereby providing a unique insulin independent method of treatment of diabetes. OBJECTIVE/ METHOD: A discussion of the evolution of SGLT inhibitors as inferred from patents published from 2005 to 2009 is prefaced by a brief review of the role of SGLT in glucose transport and the clinical findings illustrating the therapeutic potential of SGLT inhibitors as anti-diabetic agents. These compounds comprise O, C and N-glycosides generated by attachment of an appropriate lipophilic aglycone component to a suitable glucose analogue. CONCLUSION: The realization that the in vivo potency of O-glucosides was markedly less than that of C-glucosides necessitated a shift in medicinal chemistry focus of the pharmaceutical companies pursuing SGLT2 inhibitors. Particular emphasis is placed on the strategy that each used to circumvent the constraints imposed by prior art while utilizing a common pharmacophore. The role of SGLT2 inhibitors for treatment of diabetes will be established by the outcome of the five compounds in advanced clinical trials.
Authors: Huiqiang Zhou; Dana P Danger; Steven T Dock; Lora Hawley; Shane G Roller; Chari D Smith; Anthony L Handlon Journal: ACS Med Chem Lett Date: 2010-01-29 Impact factor: 4.345
Authors: Tristan S Maurer; Avijit Ghosh; Nahor Haddish-Berhane; Aarti Sawant-Basak; Carine M Boustany-Kari; Li She; Michael T Leininger; Tong Zhu; Meera Tugnait; Xin Yang; Emi Kimoto; Vincent Mascitti; Ralph P Robinson Journal: AAPS J Date: 2011-08-26 Impact factor: 4.009
Authors: B Zambrowicz; J Freiman; P M Brown; K S Frazier; A Turnage; J Bronner; D Ruff; M Shadoan; P Banks; F Mseeh; D B Rawlins; N C Goodwin; R Mabon; B A Harrison; A Wilson; A Sands; D R Powell Journal: Clin Pharmacol Ther Date: 2012-07-04 Impact factor: 6.875
Authors: Jean M Whaley; Mark Tirmenstein; Timothy P Reilly; Simon M Poucher; Joanne Saye; Shamik Parikh; James F List Journal: Diabetes Metab Syndr Obes Date: 2012-07-23 Impact factor: 3.168